{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:27:07Z","timestamp":1792261627311,"version":"4.4.0"},"reference-count":88,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Celiac disease (CeD) is a chronic autoimmune enteropathy triggered by dietary gluten in genetically predisposed individuals. Currently, a gluten\u2010free diet (GFD) is the only available treatment, being effective in improving mucosal health and symptoms. However, a considerable percentage of celiacs continue to exhibit residual mucosal damage and symptoms. In addition, dietary lapses, and social and nutritional problems pose difficulties with the GFD. Hence, there is an unmet need for new treatments in CeD, driving the development of pharmacologic interventions, with several new drugs in various stages of clinical development. These drugs target distinct steps in the immune pathology of CeD and are intended for patients who continue to experience symptoms despite trying to follow a GFD. Also, the treatment should heal the defective small intestinal mucosa, which is believed to be linked to the risk of long\u2010term complications. This review summarizes emerging CeD therapies, covering trial progress, mechanisms, and potential clinical applications.<\/jats:p>","DOI":"10.1002\/ueg2.70222","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T14:59:29Z","timestamp":1777129169000},"source":"Crossref","is-referenced-by-count":2,"title":["Upcoming Treatments in Celiac Disease: From Luminal Enzymes to Oral Immune Tolerance"],"prefix":"10.1002","volume":"14","author":[{"given":"Juha","family":"Taavela","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health Technology Celiac Disease Research Center Tampere University  Tampere Finland"},{"name":"Department of Gastroenterology and Alimentary Tract Surgery Tampere University Hospital Wellbeing Services County of Pirkanmaa  Tampere Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Elli","sequence":"additional","affiliation":[{"name":"Center for Prevention and Diagnosis of Celiac Disease Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico  Milano Italy"},{"name":"Department of Pathophysiology and Transplantation University of Milan  Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Bouma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology Amsterdam Gastroenterology Endocrinology Metabolism Amsterdam University Medical Centers  Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-9654","authenticated-orcid":false,"given":"Jason A.","family":"Tye\u2010Din","sequence":"additional","affiliation":[{"name":"Immunology Division Walter and Eliza Hall Institute  Parkville Victoria Australia"},{"name":"Department of Gastroenterology the Royal Melbourne Hospital  Parkville Victoria Australia"},{"name":"The Murdoch Children's Research Institute  Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef","family":"Schuppan","sequence":"additional","affiliation":[{"name":"Institute of Translational Immunology and Coeliac Centre Johannes Gutenberg University Mainz  Mainz Germany"},{"name":"Division of Gastroenterology Beth Israel Deaconess Medical Center Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut E. A.","family":"Lundin","sequence":"additional","affiliation":[{"name":"Norwegian Coeliac Disease Research Centre Institute of Clinical Medicine University of Oslo  Oslo Norway"},{"name":"Department of Gastroenterology Oslo University Hospital Rikshospitalet  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schumann","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Infectious Diseases and Rheumatology Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin Corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17803"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0797\u2010797"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575\u2010023\u201000872\u20102"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.10"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ygh2.380"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2021.1930146"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.02.050"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/85.1.160"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2020.07.010"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.05.002"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916\u2010020\u201001828\u2010y"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40795\u2010020\u201000390\u20103"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.02.031"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032441"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(22)00428\u20109"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(19)30264\u2010X"},{"key":"e_1_2_12_18_1","unstructured":"D.Schuppan K. E. A.Lundin J.Isola et\u00a0al. \u201cClinical Histologic and Safety Outcomes of ZED1227 Treatment in Symptomatic Celiac Disease Patients: Results From the Phase 2B CEC\u2010004\/CEL Randomized Clinical Trials \u201dUEGWeek2025accessed December 8 2025 https:\/\/programme.ueg.eu\/2025\/#\/week\/details\/presentations\/986."},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(25)01287-9"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403\u2010024\u201003784\u20106"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.10.031"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.07.071"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.11.004"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001755"},{"key":"e_1_2_12_25_1","unstructured":"\u201cPRV\u2010015 in Gluten\u2010free Diet Non\u2010responsive Celiac Disease (PROACTIVE) \u201dClinicalTrials.gov accessed December 8 2025 https:\/\/clinicaltrials.gov\/study\/NCT04424927."},{"key":"e_1_2_12_26_1","unstructured":"V.Schnir M.Rigby M.Calota Raluca et\u00a0al. \u201cDeveloping TEV\u201053408 for the Treatment of Celiac Disease: Summary of Preliminary Results from the First in Human Phase 1 Study in Healthy Volunteers \u201dDDW(2025). accessed December 9 2025 https:\/\/eposters.ddw.org\/ddw\/2024\/ddw\u20102024\/415308\/dikla.gutman.developing.tev\u201053408.for.the.treatment.of.celiac.disease.summary.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Aspeaker%3D993542%2Alabel%3D27463."},{"key":"e_1_2_12_27_1","article-title":"FB102 Prevents Histological Damage and Mitigates Gluten Challenge\u2010Induced Symptoms in a Celiac Disease Phase 1b Study","author":"Tye\u2010Din J.","year":"2025","journal-title":"Tampere Celiac Symposium"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620\u2010016\u20104426\u20105"},{"key":"e_1_2_12_29_1","unstructured":"\u201cTakeda Pipeline \u201dTakeda Pharmaceutical Company Limited accessed December 9 2025 https:\/\/www.takeda.com\/science\/pipeline\/."},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2017.1332553"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(24)00248\u20106"},{"key":"e_1_2_12_32_1","article-title":"IMU\u2010856, an Orally Available Epigenetic Modulator of Barrier Regeneration, Showed Positive Effects on Gut Hormone Levels in Celiac Disease Patients in a Phase 1 Clinical Study","author":"Schreieck A.","year":"2025","journal-title":"UEGWeek"},{"key":"e_1_2_12_33_1","unstructured":"E.Hare C.Haines M.Hsu et\u00a0al. \u201cDiscovery of a Novel High Affinity Anti\u2010Human CD122 Antagonist Monoclonal Antibody (ANB033) That Abrogates IL\u20102 and IL\u201015 Signaling for the Treatment of T Cell\u2010Mediated Inflammatory and Autoimmune Diseases \u201d accessed December 9 2025 https:\/\/www.anaptysbio.com\/wp\u2010content\/uploads\/ANB033\u2010Poster\u2010FOCIS\u20102023_FINAL.pdf."},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2024.110259"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1452537"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i11.1545"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010019\u201048299\u20107"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.05.022"},{"key":"e_1_2_12_39_1","unstructured":"\u201c9 Meters Discontinues Phase 3 Clinical Trial for Potential Celiac Disease Drug Larazotide \u201d accessed 9 December 2025 https:\/\/celiac.org\/2022\/06\/21\/9\u2010meters\u2010discontinues\u2010phase\u20103\u2010clinical\u2010trial\u2010for\u2010potential\u2010celiac\u2010disease\u2010drug\u2010larazotide\/."},{"key":"e_1_2_12_40_1","unstructured":"\u201cPositive Symptom Data From Its Phase 2 Trial Evaluating KAN\u2010101 for the Treatment of Celiac Disease \u201d accessed 8 December 2025 https:\/\/www.biospace.com\/press\u2010releases\/anokion\u2010announces\u2010positive\u2010symptom\u2010data\u2010from\u2010its\u2010phase\u20102\u2010trial\u2010evaluating\u2010kan\u2010101\u2010for\u2010the\u2010treatment\u2010of\u2010celiac\u2010disease."},{"key":"e_1_2_12_41_1","unstructured":"\u201cAmgen Pipeline \u201d accessed 9 December 2025 https:\/\/www.amgenpipeline.com\/."},{"key":"e_1_2_12_42_1","article-title":"Efficacy and Safety of the Glutenase TAK\u2010062 in Patients With Celiac Disease on a Gluten\u2010Free Diet: A Phase 2, Randomised, Double\u2010Blind, Placebo\u2010Controlled Study","author":"Elli L.","year":"2025","journal-title":"UEGWeek"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70301"},{"key":"e_1_2_12_44_1","unstructured":"\u201cProtagonist Pipeline \u201dProtagonist Therapeutics Inc. \u00a0accessed December 9 2025 https:\/\/www.protagonist\u2010inc.com\/product\u2010pipeline."},{"key":"e_1_2_12_45_1","doi-asserted-by":"crossref","unstructured":"\u201cGlaxo Smith Kline: Full Year and Q4 2022 Results \u201d accessed 9 December 2025 https:\/\/www.gsk.com\/media\/hi5lpxae\/fy\u20102022\u2010results\u2010slides.pdf.","DOI":"10.1016\/j.fopow.2022.02.017"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.3920\/BM2020.0016"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000274"},{"key":"e_1_2_12_48_1","unstructured":"\u201cActiobio Pipeline \u201dActio Biosciences accessed December 9 2025 https:\/\/actiobiosciences.com\/pipeline\/."},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869669"},{"key":"e_1_2_12_50_1","unstructured":"FDA \u201cCeliac Disease: Developing Drugs for Adjunctive Treatment to a Gluten\u2010Free Diet \u201d accessed February 5 2026 https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/celiac\u2010disease\u2010developing\u2010drugs\u2010adjunctive\u2010treatment\u2010gluten\u2010free\u2010diet."},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.11.001"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.03.019"},{"key":"e_1_2_12_53_1","article-title":"Assessment of Histologic Endpoints and Performance in the TAK\u2010062 Phase 2 Trial","author":"Maxwell J. R.","year":"2025","journal-title":"UEGWeek"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.111609"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.974771"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109972"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101782"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.02.008"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102020\u2010323829"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.276"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0698\u2010713"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/73200"},{"key":"e_1_2_12_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1074\u20105521(03)00045\u20100"},{"key":"e_1_2_12_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2010.11.004"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.21.1.148\u2010155.2001"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.01.040"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells11101667"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/0198\u20108859(94)90079\u20105"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.1.187"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010019\u20100403\u20109"},{"key":"e_1_2_12_71_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501152"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.02.015"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575\u2010024\u201000895\u20103"},{"key":"e_1_2_12_74_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.04.048"},{"key":"e_1_2_12_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(17)30110\u20103"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw7756"},{"key":"e_1_2_12_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(23)00107\u20103"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661622"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.03.014"},{"key":"e_1_2_12_80_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1542380"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010020\u20102003\u20108"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.03.042"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI41344"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(19)30265\u20101"},{"key":"e_1_2_12_85_1","unstructured":"\u201cGilde Healthcare Announces Calypso to Be Acquired by Novartis for up to USD 425M \u201d accessed 1 January 2026 https:\/\/gildehealthcare.com\/de\/news\/all\/gilde\u2010healthcare\u2010announces\u2010calypso\u2010to\u2010be\u2010acquired\u2010by\u2010novartis\u2010for\u2010up\u2010to\u2010usd\u2010425m\/."},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.03.059"},{"key":"e_1_2_12_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13988"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.02.005"},{"key":"e_1_2_12_89_1","volume-title":"Reflection Paper on the Use of Extrapolation in the Development of Medicines for Paediatrics (EMA\/189724\/2018)","author":"European Medicines Agency","year":"2018"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.70222","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ueg2.70222","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ueg2.70222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:03:38Z","timestamp":1780733018000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ueg2.70222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/ueg2.70222"],"URL":"https:\/\/doi.org\/10.1002\/ueg2.70222","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"e70222"}}